Nintedanib Ipf Stada (Nintedanib)

• Nintedanib is used to target fibrotic lung disease and specific lung‑cancer pathways.
• Idiopathic pulmonary fibrosis: slows disease progression and decline in lung function.
• Systemic sclerosis‑associated interstitial lung disease: reduces the rate of forced vital capacity loss.
• Non‑small cell lung cancer: inhibits tumor angiogenesis and growth when used in appropriate therapeutic regimens.

• Nintedanib inhibits multiple receptor tyrosine kinases—including vascular endothelial growth factor receptors (VEGFR 1‑3), fibroblast growth factor receptors (FGFR 1‑3), and platelet‑derived growth factor receptors (PDGFR‑α/β). By blocking these pathways, it reduces fibroblast proliferation, extracellular matrix deposition, and angiogenesis, thereby limiting fibrotic remodeling and tumor vascularization.

Nintedanib may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Diarrhea: frequent loose stools, often mild to moderate.
• Nausea: sensation of unease in the stomach, may lead to reduced appetite.
• Vomiting: occasional episodes, usually self‑limited.
• Elevated liver enzymes: mild increases in ALT/AST observed in routine monitoring.

Serious or Rare Side Effects

• Hepatotoxicity: significant liver injury requiring discontinuation.
• Bleeding events: gastrointestinal or other hemorrhage, especially with anticoagulants.
• Cardiovascular events: myocardial infarction or stroke in predisposed patients.
• Severe infections: opportunistic infections in immunocompromised individuals.
• Gastrointestinal perforation: rare but potentially life‑threatening.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters.

• Liver function: assess baseline ALT/AST and monitor periodically.
• Bleeding risk: avoid concomitant use with strong anticoagulants unless necessary.
• Cardiovascular health: screen for history of ischemic heart disease or stroke.
• Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with obstetric specialist.
• Store below 25°C: keep in the original pack, protect from moisture.

Nintedanib may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nintedanib exposure.
• P‑gp inhibitors (e.g., verapamil): can raise plasma concentrations.
• Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
• Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for bleeding.
• St. John’s wort: potential reduction in drug levels.
• High‑fat meals: may modestly affect absorption; advise consistent intake.